RecruitingNot Applicable

Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock

China30 participantsStarted 2025-09-01

Plain-language summary

This study prospectively observes changes in critical closing pressure (Pcc) and derived hemodynamic parameters in mechanically ventilated distributive shock patients when clinically indicated norepinephrine dose reduction is performed by the attending physician. Pcc is measured before and 30 minutes after dose reduction using a stepwise inspiratory hold maneuver via PiCCO monitoring.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Adult distributive shock patients aged ≥18 years;
. Receiving norepinephrine infusion with MAP in the 75-85 mmHg range;
. PiCCO catheter in situ;
. Under mechanical ventilation;
. Clinically indicated norepinephrine dose reduction per attending physician judgment.

Exclusion criteria

. Significant cardiac arrhythmia affecting CO measurement reliability;
. Contraindication to airway plateau pressure maneuver;

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in critical closing pressure (Pcc, Unit: mmHg) before and after norepinephrine dose reduction

Timeframe: Baseline and 30 minutes after norepinephrine dose reduction

Change in tissue perfusion pressure (TPP, unit: mmHg) before and after norepinephrine dose reduction

Timeframe: Baseline and 30 minutes after norepinephrine dose reduction

Trial details

NCT IDNCT07653659

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-07-01

Contact for this trial

Bin Du, Dr

86+15136289398 sunyaliii@163.com

View on ClinicalTrials.gov More Distributive Shock trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Adult distributive shock patients aged ≥18 years;
. Receiving norepinephrine infusion with MAP in the 75-85 mmHg range;
. PiCCO catheter in situ;
. Under mechanical ventilation;
. Clinically indicated norepinephrine dose reduction per attending physician judgment.

Exclusion criteria

. Significant cardiac arrhythmia affecting CO measurement reliability;
. Contraindication to airway plateau pressure maneuver;

What they're measuring

Change in critical closing pressure (Pcc, Unit: mmHg) before and after norepinephrine dose reduction

Timeframe: Baseline and 30 minutes after norepinephrine dose reduction

Change in tissue perfusion pressure (TPP, unit: mmHg) before and after norepinephrine dose reduction

Timeframe: Baseline and 30 minutes after norepinephrine dose reduction